Tanya Coleman

PhD

Tanya has more than 20 years’ experience in pharmaceutical project teams as a nonclinical ADME specialist and clinical pharmacologist. She held project and team leader roles at several large pharma companies before becoming an independent consultant.  In these roles, she has supported research teams as well as early and late clinical development projects, with a particular strength in oncology and infection.  Tanya has also led specialist groups in in vitro metabolism and drug transporters.

Olivia Turner

Olivia has recently completed her second year studying Biomedical Sciences at Sheffield University. Choosing to take the Physiology and Pharmacology route in her second year, Olivia is currently on a placement year (jointly with ApconiX and Aptus Clinical) to gain greater understanding of drug development and the pharmaceutical industry. She hopes to be able to finish her degree and move straight to studying for a Ph.D. Versatile, enthusiastic and highly adaptive, Olivia is a great addition to the ApconiX office as she learns about the essential role of drug safety in pharmaceuticals as well as what it’s like to be part of a growing company.

Read more here

Andrew Winkley

PhD, DABT

Andrew has over 20 years of drug safety experience in industry at AstraZeneca and Vertex. He has a broad scientific background that includes mechanistic and regulatory toxicology, and biochemistry. His drug development experience covers the complete life cycle of drug development from discovery to late-stage development in several therapeutic areas including orphan indications, neuroscience, pain therapeutics, inflammatory diseases, infectious diseases, and oncology. Andrew has been involved in bringing several candidate molecules to clinical trials and most recently completed an NDA/MAA for a cystic fibrosis drug. Andrew is a highly adaptive project toxicologist who can assimilate and interpret a broad range of data from various disciplines to provide clear guidance to the project team.

Dr Paul Duffy

PhD, ERT, FBTS

Paul is senior project toxicologist with particular expertise in new modalities including RNA therapeutics and regenerative medicines. He is an extremely highly experienced project toxicologist with invaluable submission experience in multiple territories including repurposing of existing drug projects for new applications. He has served on the BTS Executive Committee since 2006, and has many publications in peer reviewed journals. Paul is former senior project toxicologist at AstraZeneca and a former board member of Stem cells for Safer Medicines (SC4SM).

Marie Cumberbatch

MSc

Marie is an established immunologist with over 30 years of experience gained in industry and academia. She has specific immune expertise in oncology and toxicology, most recently in the field of immuno-oncology biomarkers for efficacy, mode of action, patient selection and safety across all phases of the drug discovery process from early target identification through to clinical trials. Marie has many peer reviewed publications in her specialist area of immunology and is a former team leader the AstraZeneca Oncology Translation Sciences.

Dr Damian Deavall

PhD

Damian is a project leader with broad expertise in global drug development across multiple modalities, including small molecules, antibodies, peptides, oligonucleotides, therapeutic viruses and vaccines. He has 20 years of experience in the pharmaceutical industry from early phase discovery, through development to registration across multiple therapy areas including oncology, infectious disease and metabolic disorders. He has led the safety assessment of more than 30 candidate drug programmes, bringing new therapies to clinical trials at all phases and completing marketing approval applications in the EU and US. He specializes in leading and managing drug safety programmes within complex alliances and partnerships.  Damian brings wit and wisdom to projects to drive a cross-discipline collaboration.

Dr Peter Ballard

PhD

Peter is a senior drug metabolism and pharmacokinetic (DMPK) expert with extensive experience in global discovery and development projects. He has a proven track record of international project delivery from early drug discovery through to development and compound registration from over 30 years in the pharmaceutical industry and has maintained a high academic profile with more than 30 publications in peer reviewed journals and presentations at international conference.

Dr Jane Stewart

PhD, ERT, BVM&S, MRCVS

Jane is a senior toxicologist with world leading expertise in reproductive toxicology and the safety assessment of pharmaceuticals. Jane is renowned for her expertise in problem solving for general and reproductive toxicology as well as in the investigation of endocrine effects and carcinogenesis. Jane has authored numerous pregnancy labels and has helped draft international testing guidelines for pharmaceuticals. Jane is a PhD qualified veterinarian with a degree in pathological sciences.  Jane is known for her analytical mindset and ability to identify and resolve key issues.